- Email: [email protected]
P3.11-002 Immunotherapies and Lung Cancer: Educating the Global Lung Cancer Community
November 2017 Background: Most of lung cancer patients diagnosed in advanced stage. The reasons for the delay of the diagnosis might be from patient and/or health care system. Currently, Indonesia, as a developing country in Asia, has National Health Insurance System (Jaminan Kesehatan Nasional) of which the patients is feasibly referred to the referral hospital without worrying the cost. In Persahabatan Hospital-the National Referral for Respiratory Diseases many cases have diagnostic delayed that might contribute to the prognosis. We had been conducting a study to evaluate diagnostic time and diagnostic cost to diagnose lung cancer. Method: We conducted an observational study in Persahabatan Hospital Jakarta of which newly diagnosed lung cancer patients were reviewed. We evaluated the time and cost needed from the first visit until definitive diagnosis by histopathology obtained. We also evaluated the factors that have correlated with time and cost of lung cancer diagnosis. Result: One hundred and ten subjects were enrolled in this study. Eighty four (76,36%) were male and 26 (23,64%) were female. The median age was 57 years old with range 26 to 86 years old. Data have shown that 53 (48,2%) subjects were diagnosed under target time ( less than 2 weeks) but 57 subjects (51,8%) had diagnostic time more than 2 weeks. The median time of diagnostic was 15 days with the range of 1 to 68 days. Diagnostic delay was correlated with: early stage of the diseases, good performance status, no financial resource. The median cost of diagnosis was 13.025.381 Rupiahs (around 1000 US$) with range Rp. 1.083.000,- to Rp156.285.000,- (<100US$ to 11.000 US$). Subject who came with advanced stage, poor performance status, had complication of lung cancer and referred to private hospitals had higher diagnostic cost. Conclusion: Median diagnostic time of lung cancer in Persahabatan Hospital Jakarta Indonesia was 15 days ranging from 1 to 86 days. Diagnostic time correlated with stage at admission, performance status at admission and financial support. The median cost of diagnosis was Rp. 13.025.381,- (around 1000 US$) with the range of Rp. 1.083.000,- to Rp156.285.000,(< 100US$ to 10.000 US$). Cost of lung cancer diagnosis correlated with stage at admission, performance status at admission, source of financial support and complication related to lung cancer. Keywords: diagnostic time, lung cancer, Developing Country
P3.11-002 Immunotherapies and Lung Cancer: Educating the Global Lung Cancer Community M. Rigney,1 L. Dornan,2 W. Boerckel3 1Support Initiatives, Lung Cancer Alliance, Washington, DC/US, 2Roy Castle Lung Cancer Foundation, Glasgow/GB, 3Programs Division, Cancer Care, New York, NY/US Background: Established in 2001, the Global Lung Cancer Coalition (GLCC) is the international ’voice’ of lung cancer patients. Comprised of 35 non-government patient organizations in 24 countries and the UK, nearly half of member organizations are run by fewer than five staff or are completely volunteer-run. Several meet the criteria of developing countries under the United Nations definition. The option of immunotherapy treatment is still relatively new in lung cancer and smaller, under-resourced member organizations have neither the expertise nor capacity to create credible educational materials on such a complex subject. The goal of this project was to offer information on immunotherapies to educate the global lung cancer community. Method: Created by coalition member representatives and reviewed by medical experts, the Immunotherapy and Lung Cancer factsheet provides an overview of immunotherapies and how they work. It has been professionally
Abstracts
S2313
translated into the 17 primary languages of GLCC organizations and is available on the GLCC website. Member and non-member organizations and individuals can download the factsheet to help patients all over the world understand this new treatment option for lung cancer. Result: In the first six months after the October 2016 re-launch of the GLCC website, the factsheet was downloaded 276 times. At the December 2016 annual in-person meeting of GLCC, the coalition voted to prioritize and expand the effort to produce and translate additional educational materials. GLCC members are currently working on lung cancer screening and smoking cessation materials that will also be translated. Conclusion: An international coalition can take the lead in providing not just members but the broader global lung cancer community access to resources otherwise unavailable to them. Available in Chinese, Japanese, Danish, Slovenian, Dutch, Bulgarian, Swedish, German, Spanish, Italian, French, Norwegian, Turkish, Hebrew and English, the Immunotherapy and Lung Cancer factsheet, as well as future materials, are available to individuals, cancer providers and organizations from anywhere in the world to download, print and distribute. Keywords: Immunotherapy, Education
P3.11-003 Addario Lung Cancer Foundation Patient Education Handbooks Fill a Health Literacy Void for Patients and Nurse Navigators L. Fine, D. Hicks Addario Lung Cancer Foundation, San Carlos/US Background: A lung cancer diagnosis is devastating and patients are often left in shock and seeking trusted resources. The Addario Lung Cancer Foundation (ALCF) provides patient education and support resources, including the patient education handbook. The handbook is a comprehensive resource on lung cancer presented in an easy-to-navigate format, written for the general public, produced in multiple languages and updated to keep pace with emerging advancements. Previous studies have shown that health literacy is correlated with patient engagement and outcomes. The handbook fills a void for patients by providing physician-vetted information on all aspects of lung cancer diagnosis and treatment options. Method: Two studies were conducted to assess the value of the handbook to patients and nurse navigators. The first study was a qualitative market research study that included a total of 26 patient interviews, conducted by an independent market research firm in a blinded format. The second study was the COE Impact Study which assessed the usage of ALCF resources by 15 Centers of Excellence (COE) members (a network of community hospitals) through an online survey format. Result: Overall, patients had positive ratings for all ALCF resources and rated the handbook highest on a 1-5 point scale system (4.4) among the resources. Patients commented that the handbook is a “one-stop-shop” for everything they need to know about a lung cancer diagnosis. Patients noted it would be most valuable to have at the time of diagnosis but that it can help at any point in their patient journey. It delivers information in a straightforward way, mapping out treatment options and next steps and empowering patients to help them manage side effects and related lifestyle issues. Nurse navigators also rated the handbook highest among ALCF patient resources and many make the handbook part of the diagnosis conversation with each patient. Conclusion: The patient education handbook is a valuable tool for patients and nurse navigators, especially at diagnosis when the need for trusted information is greatest. Opportunities exist to continuously improve the patient education handbook including, reformatting it to be modular,
P3.11-002 Immunotherapies and Lung Cancer: Educating the Global Lung Cancer Community M. Rigney,1 L. Dornan,2 W. Boerckel3 1Support Initiatives, Lung Cancer Alliance, Washington, DC/US, 2Roy Castle Lung Cancer Foundation, Glasgow/GB, 3Programs Division, Cancer Care, New York, NY/US Background: Established in 2001, the Global Lung Cancer Coalition (GLCC) is the international ’voice’ of lung cancer patients. Comprised of 35 non-government patient organizations in 24 countries and the UK, nearly half of member organizations are run by fewer than five staff or are completely volunteer-run. Several meet the criteria of developing countries under the United Nations definition. The option of immunotherapy treatment is still relatively new in lung cancer and smaller, under-resourced member organizations have neither the expertise nor capacity to create credible educational materials on such a complex subject. The goal of this project was to offer information on immunotherapies to educate the global lung cancer community. Method: Created by coalition member representatives and reviewed by medical experts, the Immunotherapy and Lung Cancer factsheet provides an overview of immunotherapies and how they work. It has been professionally
Abstracts
S2313
translated into the 17 primary languages of GLCC organizations and is available on the GLCC website. Member and non-member organizations and individuals can download the factsheet to help patients all over the world understand this new treatment option for lung cancer. Result: In the first six months after the October 2016 re-launch of the GLCC website, the factsheet was downloaded 276 times. At the December 2016 annual in-person meeting of GLCC, the coalition voted to prioritize and expand the effort to produce and translate additional educational materials. GLCC members are currently working on lung cancer screening and smoking cessation materials that will also be translated. Conclusion: An international coalition can take the lead in providing not just members but the broader global lung cancer community access to resources otherwise unavailable to them. Available in Chinese, Japanese, Danish, Slovenian, Dutch, Bulgarian, Swedish, German, Spanish, Italian, French, Norwegian, Turkish, Hebrew and English, the Immunotherapy and Lung Cancer factsheet, as well as future materials, are available to individuals, cancer providers and organizations from anywhere in the world to download, print and distribute. Keywords: Immunotherapy, Education
P3.11-003 Addario Lung Cancer Foundation Patient Education Handbooks Fill a Health Literacy Void for Patients and Nurse Navigators L. Fine, D. Hicks Addario Lung Cancer Foundation, San Carlos/US Background: A lung cancer diagnosis is devastating and patients are often left in shock and seeking trusted resources. The Addario Lung Cancer Foundation (ALCF) provides patient education and support resources, including the patient education handbook. The handbook is a comprehensive resource on lung cancer presented in an easy-to-navigate format, written for the general public, produced in multiple languages and updated to keep pace with emerging advancements. Previous studies have shown that health literacy is correlated with patient engagement and outcomes. The handbook fills a void for patients by providing physician-vetted information on all aspects of lung cancer diagnosis and treatment options. Method: Two studies were conducted to assess the value of the handbook to patients and nurse navigators. The first study was a qualitative market research study that included a total of 26 patient interviews, conducted by an independent market research firm in a blinded format. The second study was the COE Impact Study which assessed the usage of ALCF resources by 15 Centers of Excellence (COE) members (a network of community hospitals) through an online survey format. Result: Overall, patients had positive ratings for all ALCF resources and rated the handbook highest on a 1-5 point scale system (4.4) among the resources. Patients commented that the handbook is a “one-stop-shop” for everything they need to know about a lung cancer diagnosis. Patients noted it would be most valuable to have at the time of diagnosis but that it can help at any point in their patient journey. It delivers information in a straightforward way, mapping out treatment options and next steps and empowering patients to help them manage side effects and related lifestyle issues. Nurse navigators also rated the handbook highest among ALCF patient resources and many make the handbook part of the diagnosis conversation with each patient. Conclusion: The patient education handbook is a valuable tool for patients and nurse navigators, especially at diagnosis when the need for trusted information is greatest. Opportunities exist to continuously improve the patient education handbook including, reformatting it to be modular,